| A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (NCT05181618) | Hoffmann-La Roche | 2022-06-20 |
| A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (NCT05265286) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2022-04-14 |
| A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (NCT04864743) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2021-06-22 |
| Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform (NCT02196207) | Margaret Ragni | 2020-08-01 |
| Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A (NCT04046848) | Octapharma | 2019-07-03 |
| Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A (NCT03376516) | Octapharma | 2017-11-22 |
| Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A (NCT02954575) | Octapharma | 2016-12-01 |
| Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (NCT02502149) | Bioverativ Therapeutics Inc. | 2015-08-01 |
| An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A (NCT02172950) | CSL Behring | 2014-10-13 |
| Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII (NCT01992549) | Octapharma | 2014-04-01 |
| Pharmacokinetics of rFVIIIFc at Two Vial Strengths (NCT02083965) | Bioverativ Therapeutics Inc. | 2014-03-01 |
| Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A (NCT01405742) | University of Pittsburgh | 2012-07-01 |
| Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs) (NCT01341912) | Octapharma | 2011-06-01 |
| Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A (NCT01181128) | Bioverativ Therapeutics Inc. | 2010-11-01 |
| Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A (NCT01125813) | Octapharma | 2010-06-01 |
| Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A (NCT01027377) | Bioverativ Therapeutics Inc. | 2009-12-01 |
| Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) (NCT01051076) | City of Hope Medical Center | 2009-11-03 |
| Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive (NCT01051544) | City of Hope Medical Center | 2009-09-25 |
| Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A (NCT00323856) | Grifols Biologicals, LLC | 2003-04-08 |
| Canadian Hemophilia Prophylaxis Study (NCT01085344) | The Hospital for Sick Children | 1997-06-26 |